Navigation Links
AcelRx Pharmaceuticals Reports Third Quarter 2012 Financial Results
Date:11/6/2012

REDWOOD CITY, Calif., Nov. 6, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2012 and provided a corporate update.

Net loss for the third quarter of 2012 was $8.6 million, or $0.38 per share, compared with a net loss of $5.8 million, or $0.30 per share, for the third quarter of 2011.  During the third quarter of 2012, AcelRx recognized revenue of $166,000 resulting from reimbursement for work completed under a research grant from the U.S. Army Medical Research and Materiel Command, or USAMRMC, for development of its ARX-04 product candidate, a single dose Sufentanil NanoTab® for the treatment of moderate-to-severe acute pain. 

Research and development expenses for the third quarter totaled $6.9 million, compared with $3.9 million for the quarter ended September 30, 2011.  The increase was primarily due to expenditures associated with three ongoing Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain.  General and administrative expenses were $1.4 million for the quarter ended September 30, 2012, compared with $1.9 million for the third quarter of 2011.  This decrease resulted primarily from lower intellectual property and market research expenses.

For the nine months ended September 30, 2012, AcelRx reported a net loss of $22.8 million, or $1.09 per share, compared with a net loss of $13.7 million, or $0.83 per share, for the same period in 2011.  As of September 30, 2012, AcelRx had cash, cash equivalents and investments of $23.4 million, compared to $31.9 million at June
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
2. AcelRx Pharmaceuticals to Hold Third Quarter 2012 Financial Results Conference Call and Webcast on November 6, 2012
3. AcelRx Pharmaceuticals Hires Mike A. Royal, M.D. as Chief, Clinical Affairs
4. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
5. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
6. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
7. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
8. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
9. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
10. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Aug. 28, 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Regulatory and Reimbursement Landscape Poland " an essential ... in the healthcare market and provides insights into ... Most importantly, the report provides valuable insights into ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... CHARLOTTE, N.C. , Aug. 28, 2014 /PRNewswire/ ... innovation marketplace, today announced a worldwide search for ... of the senior population.  Promising ideas uncovered through ... presented to leading medical device manufacturers and healthcare ... to improve the lives of individuals age 65 ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... ... , ... , , , ... ...
... , ... ... ... ...
Cached Medicine Technology:Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 2Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 3Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 4Smith & Nephew Orthopaedics Launches Versatile VLP(TM) FOOT Plating System 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 2An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 3An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 4An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 5An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists 6
(Date:8/28/2014)... Fifty percent of adults who seek ... twenty percent of Americans claim to have fatigue that ... Adrenal Fatigue is the most common yet overlooked cause ... classic symptoms. Tasks that were once a breeze are ... didn’t cause irritation, experiencing weight gain around the middle ...
(Date:8/28/2014)... Doctors Frank DellaCroce and Scott Sullivan, ... (CRBS) and the St. Charles Surgical Hospital ... that board certified surgeon Dr. Craig Ashley Blum has ... to reconstructive breast surgery. Blum will work with the ... Trahan, and M. Whitten Wise. , “We are excited ...
(Date:8/28/2014)... August 29, 2014 Involution ... some of the healthcare industry's most pressing problems, ... radically rethink health. Involution Studios' creative team ... creating software solutions for clients including AstraZeneca, 3M ... As part of the studio's philosophy to change ...
(Date:8/28/2014)... Starting on Monday, the Mesothelioma Applied ... in Bitcoin, in addition to all the traditional ways ... at http://www.curemeso.org/bitcoin . , “As more and ... payment, we decided it was important for us to ... Melinda Kotzian. , Bitcoin is an online-only, internet ...
(Date:8/28/2014)... Skmen.com, one of the most popular suppliers of men’s ... long sleeve sweater dresses and launched a ... unveiled sweater outfits are available at discounted rates, up ... of fact, Skmen.com’s fashionable and quality items have greatly ... company’s experienced tailors are striving to make more incomparable ...
Breaking Medicine News(10 mins):Health News:Peoria AlignLife Clinics Focus on Community Education 2Health News:New Plastic Surgeon Joins Center For Restorative Breast Surgery 2Health News:Top Three Open Source Design Concepts that Rethink Health from Involution Studios 2Health News:Top Three Open Source Design Concepts that Rethink Health from Involution Studios 3Health News:Cancer Research Funding Organization Now Accepts Bitcoin Donations 2Health News:Skmen.com: Bestselling Long Sleeve Sweater Dresses Are Offered Online Now 2
... Findings suggest airway pressure treatment prevents complications, cuts readmissions ... hours of postoperative treatment with continuous positive airway pressure ... heart surgery, finds a new study. , CPAP is ... study, published in the May issue of Chest ...
... discovered gene known as DEAR1 is mutated in breast cancer ... early-onset breast cancer, a research team headed by scientists at ... in the journal PLoS Medicine . , "The ... women have recurrences in the breast, and cancers that do ...
... $1.5 Million - $3 MillionPRINCETON, N.J., May 6 ... DSCI), a manufacturer and marketer of advanced wound care products, ... private label adhesive bandages to one of the largest medical ... are expected to range between $1.5 to $3.0 million for ...
... conference focused on promoting physical activity on college ... on connecting health care providers and the public ... infiltrating college campuses nationwide. The American College of ... On Campus," a program component to address and ...
... --Leadership in Fight Against Tobacco Recognized Nationally--WASHINGTON, May ... has been named the South Regional Youth Advocate ... Kids for her leadership in the fight against ... in the nation,s capital tonight (May 6) along ...
... has potent anti-inflammatory properties and British scientists have now found that ... substance feared in biologic warfare. , ... Manhasset, NY ... British scientists have now found that it is helpful in delaying ...
Cached Medicine News:Health News:Novel gene predicts local recurrence in early onset breast cancer 2Health News:Novel gene predicts local recurrence in early onset breast cancer 3Health News:Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages 2Health News:Derma Sciences Announces New Contract With Major Medical Products Supplier for Private Label Adhesive Bandages 3Health News:'Exercise is Medicine On Campus' Launches With National Call to Action 2Health News:'Exercise is Medicine On Campus' Launches With National Call to Action 3Health News:Campaign for Tobacco-Free Kids Honors Colleen Daly of Asheville, NC As Youth Advocate of the Year 2Health News:Nicotine May Help Prevent Damage from Bioterrosim Toxin and Growth Factors in Heart Disease News from Molecular Medicine 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: